RxDoctor Payments DataLook up a doctor →

Andrew Blumenfeld, MD

Neurology · Carlsbad, CANPI 1164459913

Payments from drug & device makers

$5,068,186in general payments, 2019–2025

Across 5,243 payments — averaging $966.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3.2M
  • Teva Pharmaceuticals USA, Inc.$500K
  • Lilly USA, LLC$459K
  • Lundbeck LLC$195K
  • Amgen$178K
  • H. Lundbeck A S$143K
  • plus $427K from 54 others
$14,083in research payments, 2019–2025

Across 5 payments — averaging $2816.56 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$7K
  • Novartis$4K
  • Pfizer$3K
  • Amgen$23

What the payments were for

  • Consulting fees$1,954,61840%
  • Speaking & faculty fees$2,484,58651%
  • Grants$850%
  • Travel & lodging$397,0718%
  • Food & beverage$79,2792%
  • Education$2060%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)2,515$3,167,672
Teva Pharmaceuticals USA, Inc.507$499,610
Lilly USA, LLC613$458,504
Lundbeck LLC307$194,727
Amgen243$177,726
H. Lundbeck A S53$143,258
Bausch Health US, LLC60$84,228
Biohaven Pharmaceutical Holding Company Ltd.143$83,809
Axsome Therapeutics, Inc.88$81,180
Biohaven Pharmaceuticals, Inc.119$59,500
Pfizer165$41,733
Merz Pharmaceuticals, LLC10$17,310
Biodelivery Sciences International, Inc.8$14,023
Impel Pharmaceuticals Inc.16$10,581
Promius Pharma LLC13$5,518
Voxneuro USA Inc.1$5,250
Supernus Pharmaceuticals, Inc.50$4,882
Tonix Medicines, Inc.4$3,743
Collegium Pharmaceutical, Inc.5$3,217
Ipsen Biopharm Limited1$2,385
Sunovion Pharmaceuticals Inc.78$1,185
Currax Pharmaceuticals LLC4$1,144
Upsher-smith Laboratories LLC57$1,100
Scilex Pharmaceuticals Inc.9$920
Medtronic(3 entities)3$574
Dr.reddy's Laboratories,inc.1$525
Impel Pharmaceuticals LLC30$487
Eli Lilly6$456
Novartis21$307
Avanir Pharmaceuticals, Inc.2$245
CSL Behring9$239
Biogen8$186
Assertio Therapeutics, Inc.14$184
Genentech USA, Inc.5$160
UCB, Inc.6$154
Novo Nordisk3$151
Neurelis, Inc.6$140
Eisai Inc.5$109
Zyla Life Sciences, Inc.11$102
EMD Serono, Inc.5$99
Sanofi4$98
Jazz Pharmaceuticals Inc.3$88
Alnylam Pharmaceuticals Inc.4$87
Tersera Therapeutics LLC4$68
Vertex2$57
Acadia Pharmaceuticals Inc2$51
Argenx US, Inc.2$48
Genentech, Inc.2$47
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC2$46
Amneal Pharmaceuticals LLC2$39
Boston Scientific2$30
Neurocrine Biosciences, Inc.1$27
Forte Bio-pharma LLC1$25
Takeda Pharmaceuticals U.S.A., Inc.1$23
Avadel CNS Pharmaceuticals, LLC1$23
SK Life Science, Inc.1$22
Ipsen Biopharmaceuticals, Inc1$22
Otsuka America Pharmaceutical, Inc.1$20
Portola Pharmaceuticals, LLC1$15
AstraZeneca1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,068,186 in reported general payments places this provider in the 95th percentile of 1,996 neurology providers in California.

See all neurology providers in California

Medicare billing

Part B allowed, 2024
$259,407
Medicare patients
95
Services billed
34,211

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
QuliptaAtogepant44$61,640
Nurtec OdtRimegepant Sulfate32$54,776
UbrelvyUbrogepant29$41,648
Emgality PenGalcanezumab-Gnlm42$27,583
Ajovy AutoinjectorFremanezumab-Vfrm23$18,463
Zolmitriptan12$3,269
Gabapentin36$1,460
Candesartan Cilexetil23$1,022
Naratriptan Hcl12$478
Tizanidine Hcl18$372
Memantine Hcl25$201
Escitalopram Oxalate13$123
Topiramate15$24

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieQulipta, Ubrelvy$3,167,672$103,28873 claims
PfizerNurtec Odt$41,733$54,77632 claims
Upsher-smith Laboratories LLCTopiramate$1,100$2415 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,996 neurology providers in California.

Other neurology in Carlsbad

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →